File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/0090-1229(92)90005-9
- Scopus: eid_2-s2.0-0026683169
- PMID: 1611716
- WOS: WOS:A1992HP02400005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: T and B cell responses to neutrophil cytoplasmic antigens in systemic vasculitis
Title | T and B cell responses to neutrophil cytoplasmic antigens in systemic vasculitis |
---|---|
Authors | |
Issue Date | 1992 |
Citation | Clinical Immunology and Immunopathology, 1992, v. 63 n. 2, p. 135-141 How to Cite? |
Abstract | The systemic vasculitides (SV) are characterized by the presence of autoantibodies to neutrophil cytoplasmic antigens (ANCA). The role of T cells in SV is uncertain. We studied human and murine T cell responses to human neutrophil cytoplasmic antigens in vitro. T cells from mice immunized with the neutrophil extract showed dose-dependent antigen-specific proliferation, restricted by the MHC class II E molecule. Myeloperoxidase (MPO) was not an important target antigen for murine T cells. Peripheral blood lymphocytes (PBLs) were obtained from 36 patients with SV, 31 before the start of immunosuppressive therapy, and from 11 healthy controls. T cell responses to the neutrophil extract in vitro did not differ between patients and controls: there were only low levels of antigen-specific proliferation, and this could not be amplified by in vitro selection. In 3 patients and 2 normals, PBLs were also tested after the depletion of CD8+ cells; this did not unmask T cell reactivity to neutrophil extract. The lack of demonstrable T cell reactivity to this antigen preparation may indicate that T cells do not play an important effector role in these diseases. A solid-phase spot ELISA was adapted to demonstrate autoantibody-producing B cells in vitro. Low numbers of ANCA-producing B cells could be demonstrated in the majority of patients. B cells producing antibody to MPO could be demonstrated in most patients and in three laboratory staff, but not in normals from outside the laboratory. In 2 patients, sequential B cell spot ELISAs were performed during the introduction of therapy, and autoantibody-producing B cells rapidly decreased in number. This assay may therefore be useful in monitoring the effects of treatment at the cellular level. |
Persistent Identifier | http://hdl.handle.net/10722/195354 |
ISSN | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mathieson, PW | - |
dc.contributor.author | Lockwood, CM | - |
dc.contributor.author | Oliveira, DBG | - |
dc.date.accessioned | 2014-02-28T06:12:01Z | - |
dc.date.available | 2014-02-28T06:12:01Z | - |
dc.date.issued | 1992 | - |
dc.identifier.citation | Clinical Immunology and Immunopathology, 1992, v. 63 n. 2, p. 135-141 | - |
dc.identifier.issn | 0090-1229 | - |
dc.identifier.uri | http://hdl.handle.net/10722/195354 | - |
dc.description.abstract | The systemic vasculitides (SV) are characterized by the presence of autoantibodies to neutrophil cytoplasmic antigens (ANCA). The role of T cells in SV is uncertain. We studied human and murine T cell responses to human neutrophil cytoplasmic antigens in vitro. T cells from mice immunized with the neutrophil extract showed dose-dependent antigen-specific proliferation, restricted by the MHC class II E molecule. Myeloperoxidase (MPO) was not an important target antigen for murine T cells. Peripheral blood lymphocytes (PBLs) were obtained from 36 patients with SV, 31 before the start of immunosuppressive therapy, and from 11 healthy controls. T cell responses to the neutrophil extract in vitro did not differ between patients and controls: there were only low levels of antigen-specific proliferation, and this could not be amplified by in vitro selection. In 3 patients and 2 normals, PBLs were also tested after the depletion of CD8+ cells; this did not unmask T cell reactivity to neutrophil extract. The lack of demonstrable T cell reactivity to this antigen preparation may indicate that T cells do not play an important effector role in these diseases. A solid-phase spot ELISA was adapted to demonstrate autoantibody-producing B cells in vitro. Low numbers of ANCA-producing B cells could be demonstrated in the majority of patients. B cells producing antibody to MPO could be demonstrated in most patients and in three laboratory staff, but not in normals from outside the laboratory. In 2 patients, sequential B cell spot ELISAs were performed during the introduction of therapy, and autoantibody-producing B cells rapidly decreased in number. This assay may therefore be useful in monitoring the effects of treatment at the cellular level. | - |
dc.language | eng | - |
dc.relation.ispartof | Clinical Immunology and Immunopathology | - |
dc.title | T and B cell responses to neutrophil cytoplasmic antigens in systemic vasculitis | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/0090-1229(92)90005-9 | - |
dc.identifier.pmid | 1611716 | - |
dc.identifier.scopus | eid_2-s2.0-0026683169 | - |
dc.identifier.volume | 63 | - |
dc.identifier.issue | 2 | - |
dc.identifier.spage | 135 | - |
dc.identifier.epage | 141 | - |
dc.identifier.isi | WOS:A1992HP02400005 | - |
dc.identifier.issnl | 0090-1229 | - |